Top Ten Videos to watch

Graduates tossing caps into the air
Freddie Gray Baltimore Protests
Mid section of man in graduation gown holding diploma
Legendary Baseball Player Tony Gwynn's Family Files A Lawsuit Against Big Tobacco
ME.jailhouse#2.0117.CW Montebello City Council has approved use of a private contractor to run the n
Chicago Mayor Rahm Emanuel Addresses Police Misconduct At Chicago City Council Meeting
WWII Soldiers Standing In A Flag Draped Sunset - SIlhouette
Students Taking a College Exam
Bill Cosby Preliminary Hearing
Hillary Clinton Campaigns In Louisville, Kentucky
Worried black businesswoman at desk
Tyler Perry And Soledad O'Brien Host Gala Honoring Bishop T.D. Jakes' 35 Years Of Ministry
Teacher with group of preschoolers sitting at table
FBI Officials Discuss Apprehension Of Explosions Suspect After Three-Day Manhunt
NFC Championship - San Francisco 49ers v Atlanta Falcons
US-POLITICS-OBAMA
Protests Erupt In Chicago After Video Of Police Shooting Of Teen Is Released
24673281
US-VOTE-DEMOCRAT-SANDERS
Nine Dead After Church Shooting In Charleston
Portrait of senior African woman holding money
Medicare
President Bush Speals At Federalist Society's Gala
Police
Police Line Tape
Senior Woman's Hands
Police officers running
New Orleans Residents Return to Housing Projects
David Banner
2010 Jazz Interlude Gala
Leave a comment

Tradjenta blacksBoehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced on Thursday that Phase 3 data results of diabetes treatment pill Tradjenta® (linagliptin) showed marked improvements in African-American blood sugar. The data were presented at the American Association of Clinical Endocrinologists (AACE) 21st annual Scientific and Clinical Congress, and to date, it is the only drug of its kind to be approved at the one-dosage strength level.

SEE ALSO: Will The Real Race-Baiters Stand Up?

Researchers saw a need to address and collect data from the underrepresented data samples of African Americans in order to study how Blacks combat diabetes. This study is the first of its kind, focusing on DPP-4 inhibitors and patients with Type 2 diabetes.

“These findings support the efficacy and safety profile of linagliptin as a treatment option for African-American adult patients with Type 2 diabetes,” said lead investigator James Thrasher, MD, FACE, Arkansas Diabetes and Endocrinology Center. “As there may be differences in response to treatment among ethnic groups, an important finding of this trial is that the results are consistent with the A1C reduction seen in the linagliptin pivotal trials, which included a small sample of African-American patients.”

While Tradjenta is not recommended for persons with Type 1 diabetes, you can learn more about it here.

SEE ALSO:

NAACP’s Long History On Marriage Equality

Is Obama Avoiding Wisconsin?

Also On News One: